Neuro-oncology clinical debate: Pcv or temozolomide in combination with radiation for newly diagnosed high-grade oligodendroglioma

Michael W. Ruff, Jan Craig Buckner, Derek R. Johnson, Martin J. Van Den Bent, Marjolein Geurts

Research output: Contribution to journalArticle

Abstract

The treatment of newly diagnosed oligodendroglioma has been revolutionized in the past decade by multiple studies demonstrating that the addition of chemotherapy to radiation therapy results in a significant survival benefit. While the most direct evidence comes from clinical trials that utilized PCV, a chemotherapy regimen consisting of procarbazine, CCNU (lomustine), and vincristine, there is circumstantial evidence suggesting that the oral agent temozolomide (TMZ), which is both better tolerated and logistically simpler than PCV, may also be effective. The lack of currently available direct comparative data for PCV vs TMZ results in a diversity of practice. In this article, Ruff and Buckner argue for PCV as part of the standard-of-care regimen for newly diagnosed anaplastic oligodendroglioma, while Geurts and van den Bent defend the use of TMZ.

Original languageEnglish (US)
Pages (from-to)17-21
Number of pages5
JournalNeuro-Oncology Practice
Volume6
Issue number1
DOIs
StatePublished - Jan 30 2019

Keywords

  • glioblastoma
  • glioma
  • lomustine
  • oligodendroglioma
  • PCV
  • temozolomide

ASJC Scopus subject areas

  • Medicine (miscellaneous)

Fingerprint Dive into the research topics of 'Neuro-oncology clinical debate: Pcv or temozolomide in combination with radiation for newly diagnosed high-grade oligodendroglioma'. Together they form a unique fingerprint.

  • Cite this